Claus Tycho Bræstrup

UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany.

Gyros AB engages in the utilization of microfluidic technologies to miniaturize and automate immunoassays. Its Gyrolab xP miniaturizes, integrates, and automates analysis of samples in parallel. The firm's technology delivers immunoassay data through automated control of centrifugal and capillary forces to steer liquid flow in proprietary nanoliter-scale microfluidic structures.The company offers Gyrolab microlaboratory, in the form of a compact disk, can process samples at nanoliter scale, controlled by Gyrolab Workstation. Gyros was founded in 2000 and is headquartered in Uppsala, Sweden.

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.

Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark.

Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.

Tekniikan Akatemia -säätiö sr, also known as Technology Academy Finland (TAF), is based in Helsinki, Finland. The CEOs of the Finnish company are Mikko Salaspuro and Ainomaija Susanna Haarla. TAF awards the €1 million Millennium Technology Prize and organizes associated events and initiatives. The private company provides an international meeting ground for corporate life, academia, and policymakers, and promotes Finland's position in the community. The Millennium Technology Prize is the world's most prestigious award for breakthrough innovations that improve the quality of people's lives.

The Danish National Advanced Technology Foundation promotes research and innovation by providing funds. It offers private companies and universities the funds and the framework for developing new and important technologies. The company was founded in 2005 and is headquartered in Copenhagen, Denmark.

Bankinvest Biomedical Venture provides investment services. The company was founded in 1998 and is headquartered in Copenhagen, Denmark.

Kastan ApS is a Danish company that specializes in the rental and leasing of cars and light motor vehicles. Claus Tycho Bræstrup has been the CEO of the private company since 2008.

Aniona ApS is a private company based in Ballerup, Denmark. Jørgen Drejer has been the CEOs since incorporation. The Danish company was founded by Thomas Feldthus, Anker Gunvald Lundemose, Claus Tycho Bræstrup, Jørgen Drejer.

Ataxion, Inc. develops novel therapies for rare, debilitating, and underserved neurologic diseases. It focuses on orphan genetic disorders termed hereditary ataxias. It was founded by Josh Resnick and David Grayzel in April 2013 and is headquartered in Cambridge, MA.

Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.